Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 76
2021 193
2022 299
2023 235
2024 67

Text availability

Article attribute

Article type

Publication date

Search Results

804 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Chinese Academy of Medical Sciences COVID-19 vaccine"
Page 1
Aging in COVID-19: Vulnerability, immunity and intervention.
Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, Li T, Margolick JB, Pawelec G, Leng SX. Chen Y, et al. Ageing Res Rev. 2021 Jan;65:101205. doi: 10.1016/j.arr.2020.101205. Epub 2020 Oct 31. Ageing Res Rev. 2021. PMID: 33137510 Free PMC article. Review.
SARS-CoV-2, a beta-coronavirus, is a highly contagious respiratory pathogen that causes a disease that has been termed the 2019 coronavirus disease (COVID-19). Clinical experience thus far indicates that COVID-19 is highly heterogeneous, ranging from b …
SARS-CoV-2, a beta-coronavirus, is a highly contagious respiratory pathogen that causes a disease that has been termed the 2019 coronavirus …
Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.
Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, He P, Girsang RT, Vergara H, Akram J, Satari HI, Khaliq T, Sughra U, Celi AP, Li F, Li Y, Jiang Z, Dalimova D, Tuychiev J, Turdikulova S, Ikram A, Flores Lastra N, Ding F, Suhardono M, Fadlyana E, Yan J, Hu Z, Li C, Abdurakhmonov IY, Gao GF; ZF2001 Global Trial Group. Dai L, et al. N Engl J Med. 2022 Jun 2;386(22):2097-2111. doi: 10.1056/NEJMoa2202261. Epub 2022 May 4. N Engl J Med. 2022. PMID: 35507481 Free PMC article. Clinical Trial.
The primary end point was the occurrence of symptomatic coronavirus disease 2019 (Covid-19), as confirmed on polymerase-chain-reaction assay, at least 7 days after receipt of the third dose. A key secondary efficacy end point was the occurrence of severe-to-critical …
The primary end point was the occurrence of symptomatic coronavirus disease 2019 (Covid-19), as confirmed on polymerase-chain- …
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy.
Zong Y, Lin Y, Wei T, Cheng Q. Zong Y, et al. Adv Mater. 2023 Dec;35(51):e2303261. doi: 10.1002/adma.202303261. Epub 2023 Nov 1. Adv Mater. 2023. PMID: 37196221 Review.
Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to the success of coronavirus disease 2019 (COVID-19) mRNA vaccines (Comirnaty and Spikevax). To meet the therapeutic purpose, it is required that mRNA m …
Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to the success of coronavirus dise …
Circular RNA vaccines against SARS-CoV-2 and emerging variants.
Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H, Zhang X, Tian F, Wang C, Xiao X, Dong X, Guo L, Lu S, Yang C, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Yisimayi A, Liu S, Huang W, Cao Y, Wang Y, Zhou Z, Peng X, Wang J, Xie XS, Wei W. Qu L, et al. Cell. 2022 May 12;185(10):1728-1744.e16. doi: 10.1016/j.cell.2022.03.044. Epub 2022 Apr 1. Cell. 2022. PMID: 35460644 Free PMC article.
As the emerging variants of SARS-CoV-2 continue to drive the worldwide pandemic, there is a constant demand for vaccines that offer more effective and broad-spectrum protection. Here, we report a circular RNA (circRNA) vaccine that elicited potent neutralizing antibodies a …
As the emerging variants of SARS-CoV-2 continue to drive the worldwide pandemic, there is a constant demand for vaccines that offer m …
Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines.
Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, Hossain MG. Araf Y, et al. J Med Virol. 2022 May;94(5):1825-1832. doi: 10.1002/jmv.27588. Epub 2022 Jan 23. J Med Virol. 2022. PMID: 35023191 Free PMC article. Review.
According to preliminary data, the Omicron variant of SARS-CoV-2 has a higher risk of reinfection. On the other hand, whether the current COVID-19 vaccines could effectively resist the new strain is still under investigation. However, there is very limited in …
According to preliminary data, the Omicron variant of SARS-CoV-2 has a higher risk of reinfection. On the other hand, whether the current …
Ribosome biogenesis in disease: new players and therapeutic targets.
Jiao L, Liu Y, Yu XY, Pan X, Zhang Y, Tu J, Song YH, Li Y. Jiao L, et al. Signal Transduct Target Ther. 2023 Jan 9;8(1):15. doi: 10.1038/s41392-022-01285-4. Signal Transduct Target Ther. 2023. PMID: 36617563 Free PMC article. Review.
We also review the most recent findings of ribosome dysfunction in COVID-19 and other conditions and discuss the consequences of ribosome frameshifting, ribosome-stalling, and ribosome-collision. ...Furthermore, we review the current clinical trials, prospective …
We also review the most recent findings of ribosome dysfunction in COVID-19 and other conditions and discuss the consequences …
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Nguyen-Van-Tam JS, Patel MG, Saville BR, Marion J, Ogburn E, Allen J, Rutter H, Francis N, Thomas NPB, Evans P, Dobson M, Madden TA, Holmes J, Harris V, Png ME, Lown M, van Hecke O, Detry MA, Saunders CT, Fitzgerald M, Berry NS, Mwandigha L, Galal U, Mort S, Jani BD, Hart ND, Ahmed H, Butler D, McKenna M, Chalk J, Lavallee L, Hadley E, Cureton L, Benysek M, Andersson M, Coates M, Barrett S, Bateman C, Davies JC, Raymundo-Wood I, Ustianowski A, Carson-Stevens A, Yu LM, Little P; PANORAMIC Trial Collaborative Group. Butler CC, et al. Lancet. 2023 Jan 28;401(10373):281-293. doi: 10.1016/S0140-6736(22)02597-1. Epub 2022 Dec 22. Lancet. 2023. PMID: 36566761 Free PMC article. Clinical Trial.
BACKGROUND: The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to estab …
BACKGROUND: The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been est …
Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization.
Ye T, Jiao Z, Li X, He Z, Li Y, Yang F, Zhao X, Wang Y, Huang W, Qin M, Feng Y, Qiu Y, Yang W, Hu L, Hu Y, Zhai Y, Wang E, Yu D, Wang S, Yue H, Wang Y, Wang H, Zhu L, Ma G, Wei W. Ye T, et al. Nature. 2023 Dec;624(7992):630-638. doi: 10.1038/s41586-023-06809-8. Epub 2023 Dec 13. Nature. 2023. PMID: 38093012
The COVID-19 pandemic has fostered major advances in vaccination technologies(1-4); however, there are urgent needs for vaccines that induce mucosal immune responses and for single-dose, non-invasive administration(4-6). ...These findings support the use of t …
The COVID-19 pandemic has fostered major advances in vaccination technologies(1-4); however, there are urgent needs for vac …
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M, Yang M, Li Y, Cheng H, Yuan Y, Zhang W, Ke C, Wong G, Qi J, Qin C, Yan J, Gao GF. Dai L, et al. Cell. 2020 Aug 6;182(3):722-733.e11. doi: 10.1016/j.cell.2020.06.035. Epub 2020 Jun 28. Cell. 2020. PMID: 32645327 Free PMC article.
Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously emerging MERS/SARS caused by coronavirus (CoV) infections. ...Structure-guided design further yielded a stable version of RBD-dimer as a tandem repeat single-chain (RBD-sc-di …
Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously emerging MERS/SARS caused by coron …
804 results